• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.
【24h】

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

机译：溶瘤性呼肠孤病毒3型（亲爱的）作为头颈癌的一种新疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Locally advanced head and neck cancer carries a poor prognosis, even with standard combination (surgery, radiotherapy, chemotherapy) treatment regimens. There is a pressing need for novel therapies with activity against this tumour type. Oncolytic reovirus type 3 (Dearing) is preferentially cytotoxic in tumour cells with an activated Ras signalling pathway and represents a promising novel therapy with relevance in head and neck cancer. AREAS COVERED: In this review, we discuss the pre-clinical and clinical data that have underpinned the translational development of oncolytic reovirus thus far. In particular, we describe the iterative nature of the research programme through initial studies testing single-agent reovirus therapy and on to subsequent work in which reovirus has been combined with either radiotherapy or cytotoxic chemotherapy. We will trace the process by which oncolytic reovirus has reached Phase III evaluation in combination with carboplatin/paclitaxel in patients with platin-refractory, relapsed/metastatic head and neck cancer. EXPERT OPINION: Reovirus is a self-amplifying, cancer-selective agent that offers huge potential advantages over standard chemotherapy, targeted small molecules or monoclonal antibodies. However, it is most likely that reovirus will show efficacy and be approved in combination with standard modalities (cytotoxic chemotherapy or radiotherapy) or other targeted agents, especially those that modulate signal transduction pathways. The next 5 years are critical for the development of oncolytic reovirus as an anti-cancer therapy and hinge on the ongoing Phase III trial in head and neck cancer and other Phase II programmes.
机译：简介：即使采用标准的联合疗法（手术，放疗，化学疗法），局部晚期头颈癌的预后也较差。迫切需要具有针对这种肿瘤类型的活性的新疗法。 3型溶瘤呼肠孤病毒（Dearing）在具有激活的Ras信号通路的肿瘤细胞中优先具有细胞毒性，代表了与头颈癌相关的有前途的新疗法。涵盖的领域：在这篇综述中，我们讨论迄今为止支持溶瘤性呼肠孤病毒翻译发展的临床前和临床数据。特别是，我们通过测试单剂呼肠孤病毒治疗的初始研究以及随后的呼肠孤病毒已与放疗或细胞毒性化学疗法相结合的工作来描述该研究计划的迭代性质。我们将追踪溶癌性呼肠孤病毒与卡铂/紫杉醇联合治疗难治性铂金难治，复发/转移性头颈癌患者的过程，已达到III期评估。专家意见：呼肠孤病毒是一种自我扩增的癌症选择性药物，与标准化学疗法，靶向小分子或单克隆抗体相比，具有巨大的潜在优势。但是，呼肠孤病毒很可能会显示出功效并与标准方法（细胞毒性化学疗法或放射疗法）或其他靶向药物（尤其是调节信号转导途径的靶向药物）结合使用。接下来的5年对于溶瘤呼肠孤病毒作为一种抗癌疗法的发展至关重要，它取决于正在进行的头颈癌的III期试验和其他II期计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号